We evaluated CDL and ADCC antibody responses after immunization with either non‐adjuvanted or AS03‐adjuvanted pandemic A(H1N1)pdm09 vaccine in a subset of participants from a previously reported clinical trial,19 measuring antibody GMTs and VRs against the homologous (A/California/7/2009) strain and against a seasonal influenza heterologous strain (A/Brisbane/59/2007). The gene discussed is SGMS2; the disease is influenza.